Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
8323coverstoryaaopen_tifcxd.jpg

June 6, 2005 Cover

Volume 83, Issue 23

Patent expirations are beckoning generic drug companies, but numerous hurdles remain to a profitable business

Credit:

Full Article
Volume 83 | Issue 23

All Issues

Pharmaceuticals

Biopharmaceuticals

Patent expirations are beckoning generic drug companies, but numerous hurdles remain to a profitable business

  • The Name Game

    Chemical producers seek to define themselves in a blitz of corporate branding

  • The Nuclear Hot Potato

    As radioactive waste mounts and Yucca Mountain stalls, pressure grows for an interim storage site

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT